Abstract:In this retrospective analysis of 267 newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma patients, LVDP (L‐asparaginase, etoposide, dexamethasone and cisplatin) and GLIDE (gemcitabine, L‐asparaginase, ifosfamide, dexamethasone and etoposide) chemotherapy regimens showed similar short‐term and long‐term efficacies, with 85.5% ORR and 62.2% CR rates, and 64.3% PFS and 68.5% OS rates at a median 71‐month follow‐up. However, LVDP was associated with milder treatment‐related toxicities compared to GLIDE, even after adjusting for confounders via PSM. These findings suggest that LVDP could be a preferable option for patients with nasal‐type extranodal NK/T‐cell lymphoma. Background Nasal‐type extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a rare and aggressive type of lymphoma. The optimal chemotherapy regimen for ENKTL has not yet been established. In this study, we compared the LVDP (L‐asparaginase, etoposide, dexamethasone, and cisplatin) and GLIDE (gemcitabine, L‐asparaginase, ifosfamide, dexamethasone, and etoposide) chemotherapy regimens for the treatment of ENKTL. Methods A total of 267 patients with newly diagnosed ENKTL were included in this retrospective study. Propensity score matching (PSM) was used to adjust for confounders between the LVDP and GLIDE groups. Treatment responses, survival outcomes, and toxicities between the two groups were compared before and after PSM. Results At the end of therapy, the objective response rate (ORR) and complete response (CR) were 83.5% and 62.2%, respectively, for all patients. The ORR and CR were 85.5% and 62.2% for the LVDP group compared with 79.3% and 62.2% for the GLIDE group, respectively, and no differences between the two groups were found (ORR, p = 0.212; CR, p = 0.996). With a median 71 months follow‐up, the 5‐year progression‐free survival (PFS) and overall survival (OS) rates were 64.3% and 68.5%, respectively. The 5‐year PFS and OS were 65.6% and 70.1% for the LVDP group compared with 61.6% and 64.6% for the GLIDE group, respectively (PFS, p = 0.478; OS, p = 0162). After PSM, no significant differences in short‐term efficacy (ORR, p = 0.696; CR, p = 0.264) or long‐term efficacy (PFS, p = 0.794; OS, p = 0.867) between the two groups were identified. However, treatment‐related toxicities were milder in the LVDP group compared to the GLIDE group, even after adjusting for confounders via PSM. Conclusion In conclusion, both LVDP and GLIDE regimens are effective for the treatment of ENKTL. However, the LVDP regimen is safer than the GLIDE regimen, with milder treatment‐related toxicities. Therefore, the LVDP regimen could be a preferable option for patients with ENKTL.

Long-Term Outcomes Of Patients With Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma Treated By Etoposide, Prednisone, Vincristine, Cyclophosphamide, And Doxorubicin Regimen: A Single-Institution Experience

Long-Term Outcomes of Patients with Newly Diagnosed Nk/T-Cell Lymphoma Treated by Epoch Regimen

Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study

Long-Term Efficacy of Sequential Dice Chemotherapy with Regional Field Radiation Therapy for Stages I-Ii Natural Killer/T-Cell Lymphoma, Nasal Type: Analysis of 118 Cases

First-line LVDP (l-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Stage IE/IIE Extranodal Natural Killer/t Cell Lymphoma, Nasal Type: 13-Year Follow-Up in 135 Patients.

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

Radiation Therapy Alone Not Inferior to Chemoradiation in the Patients with Stage I Nasal Natural Killer/T-Cell Lymphoma

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.

Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I E /II E extranodal natural killer/T-cell lymphoma.

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

Clinical Characteristics and Treatment of 69 Patients with Extranodal Natural Killer T-cell Lymphoma

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (Nk/t)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study

Phase II/III Randomized Trial of CID-ATT with Radiotherapy Compared with CHOP with Radiotherapy As First-Line Treatment for Previously Untreated Early Staging Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL).

Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed by Extensive Involved-Field Radiotherapy(Eifrt) for Newly Diagnosed Stage I/Ii Extranodal Natural Killer/T-Cell Lymphoma-A Single Center Experience

Treatment outcome and prognosis of patients with stage Ⅰ—Ⅱ nasal-type natural killer/T-cell lymphoma receiving induction chemotherapy with GELOX regimen and radical radiotherapy

The Efficacy of PEG-Asp-argase-based Chemotherapy for Nasal-Type Extranodal NK/T-cell Lymphoma.

Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.